Zoniporide hydrochloride hydrate is primarily used in the field of medical research and drug development. It acts as a potent and selective inhibitor of the sodium-hydrogen exchanger isoform 1 (NHE-1), which plays a critical role in regulating intracellular pH and sodium levels. This compound is extensively studied for its potential therapeutic applications in conditions involving ischemia-reperfusion injury, such as myocardial infarction and stroke. By inhibiting NHE-1, it helps reduce cellular damage caused by the reintroduction of blood flow to tissues after a period of oxygen deprivation. Additionally, it is investigated for its potential benefits in protecting the heart during cardiac surgeries and improving outcomes in patients with heart failure. Its role in reducing inflammation and apoptosis further expands its potential applications in various other diseases.